share_log
Moomoo 24/7 ·  Mar 12 12:50
CytomX Therapeutics Shares Are Trading Lower After the Company Reported Q4 Financial Results. Also, BMO Capital Maintained a Market Perform Rating on the Stock and Lowered Its Price Target From $3.3 to $3.25
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment